# 119-s-3794: SAFE Drugs Act of 2026

119-s-3794, SAFE Drugs Act of 2026, is a 119th Congress bill sponsored by Sen. Banks, Jim [R-IN] (R-IN); status in_committee; PRIA reads it as touching household money (as of 2026-08-05).

- Canonical: https://policyrisk.com/legislation/119-s-3794
- As of: 2026-08-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-3794
- Congress: 119
- Title: SAFE Drugs Act of 2026
- Status: in_committee
- Introduced: 2026-02-05
- Sponsor: Sen. Banks, Jim [R-IN] (R-IN)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-08-05

## Summary

**Mandatory interstate reporting and clear warning labels for compounded drugs.** This bill would require compounding pharmacists and physicians who ship drugs across state lines to report serious adverse events and to file annual interstate shipment summaries, and it would force labels to warn patients the product is compounded and not FDA approved. - Patients: Labels must state the medication was compounded and is not FDA approved. Labels must also include info to report side effects like the FDA MedWatch website and a toll free number. - Compounding practitioners: Licensed pharmacists and physicians would have to report serious adverse events to three recipients and annually report if more than 5 percent of their compounded drugs are sent out of state. Reports must list practitioner details and monthly units sent to each State. - States and regulators: The Secretary would build an information sharing system to send reports to the Secretary and each receiving State. States may keep or add stricter reporting rules and hospital on‑premises compounding is excluded from these interstate rules.

## Cosponsors (1)

- Sen. Heinrich, Martin [D-NM] (D-NM), 2026-02-05T00:00:00.000Z

## Provisions PRIA read

- Warning labels for compounded medicines: benefit, low. If enacted, labels on drugs compounded for individual patients would have to say the medication was compounded for one patient and is not approved by the FDA. Labels would also have to list how to report bad effects, for example the FDA MedWatch website and a toll-free number like 1-800-FDA-1088. T…
- New reporting rules for compounded drugs: mixed, low. If enacted, this bill would require compounding pharmacists and physicians who send compounded drugs across State lines to file new reports. They would have to send any serious adverse event reports they receive to the FDA Secretary, the State where compounding occurred, and each State receiving th…

## Related bills

- 119-s-1748: Kids Online Safety Act
- 119-s-1552: Living Donor Protection Act of 2025
- 119-s-410: Love Lives On Act of 2025
- 119-s-237: Honoring Our Fallen Heroes Act of 2025
- 119-s-4429: Connected Vehicle Security Act of 2026
- 119-s-2142: GOLDEN DOME Act of 2025

## Sources
- [119-s-3794 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/3794)

## Related
- [119-s-1748: Kids Online Safety Act](https://policyrisk.com/legislation/119-s-1748)
- [119-s-1552: Living Donor Protection Act of 2025](https://policyrisk.com/legislation/119-s-1552)
- [119-s-410: Love Lives On Act of 2025](https://policyrisk.com/legislation/119-s-410)
- [119-s-237: Honoring Our Fallen Heroes Act of 2025](https://policyrisk.com/legislation/119-s-237)
- [119-s-4429: Connected Vehicle Security Act of 2026](https://policyrisk.com/legislation/119-s-4429)
- [119-s-2142: GOLDEN DOME Act of 2025](https://policyrisk.com/legislation/119-s-2142)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-3794 (as of 2026-08-05).